Individual compound research
PDL-TZ2 on its own. Review GIP and GLP-1 receptor research and the distinction between trials and catalog pairings.
Individual compound · no catalog companion established
No supporting controlled human combination study with the other catalog peptides was identified in this review. Findings for regulated medicines or clinical-trial materials do not establish equivalence or human use of this catalog vial.
Tirzepatide acts at GIP and GLP-1 receptors. Actual combination trials include tirzepatide with eloralintide, an amylin agonist, and with bimagrumab, an antibody. Those investigational combinations involve materials outside this catalog and do not validate pairings with its peptides. The Zepbound prescribing information does not recommend coadministration with another tirzepatide product or any GLP-1 receptor agonist.
Research reviewed September 5, 2026. Sources concern the stated study materials, not this catalog vial; trial registration alone does not establish a combination’s safety or efficacy.
Explore all Tirz research stacks
One compound, with its own product record and lot documentation.
1 vial
$110
PDL-TZ2 is the catalog alias for a synthetic peptide analogue in the dual incretin-receptor research class. Its laboratory record identifies the underlying analyte separately, while the catalog material is supplied as a sealed vial of lyophilized powder for analytical research.
Lot documentation published
One vial of this product.
Ask about Tirzepatide (Tirz)
Contact us for current availability and lot documentation for this product.
Laboratory research only. Goal labels describe research themes, not promised outcomes or combined-use guidance. Each product is a separate catalog record. Not for human or veterinary use.